BGM GroupBGM -3.12%53 ROE % is -1.53% as of Mar. 2025. GuruFocus rates BGM with a GF Score™ of 53/100 and a GF Value™ of $1.23 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 936 Drug Manufacturers companies, BGM Group ranks worse than 72.97% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. BGM Group's annualized net income for the quarter that ended in Mar. 2025 was $-1.72 Mil. BGM Group's average Total Stockholders Equity over the quarter that ended in Mar. 2025 was $112.43 Mil. Therefore, BGM Group's annualized ROE % for the quarter that ended in Mar. 2025 was -1.53%.
The historical rank and industry rank for BGM Group's ROE % or its related term are showing as below:
BGM'
s ROE % Range Over the Past 10 Years
Min: -16.24 Med: 10.19 Max: 38.92
Current: -3.04
During the past 8 years, BGM Group's highest ROE % was 38.92%. The lowest was -16.24%. And the median was 10.19%.
BGM's ROE % is ranked worse than 72.97% of 936
companies
in the Drug Manufacturers industry
Industry Median: 5.865
vs BGM: -3.04
BGM Group (NAS:BGM) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Mar. 2025) net income data. The Revenue data used here is two times the semi-annual (Mar. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
BGM Group ROE % Related Terms
BGM Group ROE % Historical Data
* Premium members only.
The historical data trend for BGM Group's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BGM Group's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BGM Group ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BGM Group's ROE % distribution charts can be found below:
* The bar in red indicates where BGM Group's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2025) net income data.
ROE % is displayed in the 30-year financial page.
BGM Group (BGM) has a ROE % of -1.53% as of Mar. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on BGM Group and its competitors. According to the industry distribution chart, BGM Group ranks #683 out of 936 companies in the Drug Manufacturers industry, placing it in the top 73%.
Is BGM Group's ROE % too high?
BGM Group's current ROE % is -1.53%. Based on the distribution chart, BGM Group ranks #683 out of 936 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, BGM Group has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BGM Group's ROE % compare to INCR and SCYX?
According to the Drug Manufacturers industry distribution chart, BGM Group ranks #683 out of 936 companies for ROE %. This places BGM Group in the lower half of its industry. The industry median ROE % is 5.87. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 5.87, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on BGM Group and its competitors. For the Drug Manufacturers industry, the median ROE % is 5.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BGM Group's current ROE % is -1.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BGM Group stock overvalued right now?
Based on GuruFocus' analysis, BGM Group (BGM) is currently considered Possible Value Trap. The stock's GF Value™ is $1.23, compared to a current price of $0.33 — trading 73.3% below its estimated fair value. The current ROE % is -1.53%. BGM Group's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For BGM Group (BGM), the current ROE % is -1.53% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BGM Group (BGM) Overvalued in 2026?
Based on GuruFocus' analysis, BGM Group stock appears to be undervalued.
The current stock price of $0.33 is trading 73.3% below its estimated GF Value™ of $1.23.
GuruFocus considers BGM Group to be Possible Value Trap.
Key valuation signals for BGM:
ROE %: -1.53%
GF Value™: $1.23 vs. price of $0.33 (73.3% below fair value)
No single metric tells the full story. See the BGM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BGM Group Ltd is a biopharmaceuticals, bio-extraction, and medical health business. Its product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium. Maximum revenue is from Oxytetracycline & Licorice and TCMD, followed by Heparin products and Sausage casing.
53GF Score
Get the complete analysis for BGM
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGM has been successfully added to your 
